Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of JDQ443 in KRAS G12C-mutated advanced solid tumors
CTR20211563Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of opnurasib, batoprotafib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Novartis. Started Apr 2022; status: completed.
02
Drugs
opnurasibbatoprotafib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20211563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211563.